EU-PEARL to present the potential of the platform trials framework in CTFs Annual Conference

EU-PEARL will participate in the Children’s Tumor Foundation (CTF) Annual Conference which will take place online next June 15th and 16th. This global forum focuses on building consensus and advancing translational and clinical research to improve outcomes for patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis. Every year, this event attracts nearly 500 participants worldwide who are involved in NF research and clinical care.

Rianne Oostenbrink, (MD, PhD, MSc) from the Erasmus Medical Center in Rotterdam (Netherlands) and a principal investigator in EU-PEARL will present the project’s vision and mission during the CTF’s Conference. Oostenbrink will reveal how EU-PEARL is set to build the specific Integrated Research Platform (IRP) framework on Neurofibromatosis. Once ready, this novel framework will support innovative clinical drug research of new or more effective treatments to fight NF. Ultimately, EU-PEARL will create trial-ready clinical networks in this disease, so that platform trials can be initiated shortly after the project is completed and funding secured. The presentation by Rianne Oostenbrink will take place on June 16th at 12.30 pm (NYC time).

CTF is a partner and kind contributor to EU-PEARL, an IMI funded project committed to transform the future of clinical trials by making them more efficient, agile, speedier and patient friendly.